

Index

5th Amendment of the US Constitution 61	Violent Crime Index arrest rate 53
8% Early Intervention Program 378	<i>see also</i> minority youth
8th Amendment of the US Constitution	aggression
and juvenile death penalty 241, 242–244	acute aggression treatment 309, 310–311
rights of juvenile detainees 7	“cold” aggression 311–312
14th Amendment of the US Constitution, rights	evaluation and assessment for pharmacotherapy
of juvenile detainees 7	312–314
academic achievement tests 300–301	functional overlap with psychiatric illnesses 315
academic problems	“hot” aggression 311–312
and ADHD 291	pharmacotherapy for conduct disorder
criminal behavior risk 129	314–321, 324
substance abuse risk factor 154, 158	positive, instrumental, or planned (PIP)
ADA (Americans with Disabilities Act) 234	311–312
adaptive functioning tests 301	reactive, affective, defensive, or impulsive
addiction, neurobiology of 154–156	(RADI) 311–312
ADHD (attention-deficit/hyperactivity disorder)	subtypes 311–312
and substance abuse 151, 153, 156–157	Aggression Replacement Training (ART) 373
association with academic problems 291	alcohol, effects of prenatal exposure 171–172, 257
diagnosis in delinquent youth 17–18	alcoholism, and history of childhood maltreatment
influence on recidivism 292	257–258
neuropsychological deficits and delinquency	alcoholism treatment 170
290–291	alprazolam 326–327
relationship to conduct disorder (CD)	American-Indian youth
290–291	arrest rate 52, 53
treatments for substance abusers 168–169	disproportionate minority confinement 49–50
ADHD/ADD, confusion with dyslexia 157	proportion of juvenile population 51–52
Adolescent Drinking Inventory (ADI) 161–162	Violent Crime Index arrest rate 53
adolescent neurobiological changes, substance	<i>see also</i> minority youth; Native American youth
abuse risk factor 158–159	anger regulation impairment, criminal behavior risk
Adolescent Psychopathology Scale (APS) 302, 303	factor 123–124
Adolescent Test of Problem-Solving (TOPS-A)	antidepressants 325
297–298	antipsychotics 326
African-American youth	antisocial behavior, history of enquiry into 122–123
disproportionate minority confinement	<i>see also</i> criminal behavior
49–50	anxiety disorders, and substance abuse 151,
overrepresentation in the juvenile justice	152–153
system 51–55	Asian-American youth
proportion of juvenile population 51–52	arrest rate 52, 53
rates of arrest 52, 53	disproportionate minority confinement 49–50
rates of detention 53	proportion of juvenile population 51–52
rates of petitioning 53	suicidal behavior in confinement 186
rates of residential placement 50, 51, 52	Violent Crime Index arrest rate 53
rates of waiver to adult court 53	<i>see also</i> minority youth
suicidal behavior in confinement 186	<i>Atkins v. Virginia</i> (2002) 243–244, 245

438 Index

- atomoxetine 168–169, 328
- atypical antipsychotics 326
- autonomic responses, criminal behavior risk factors 126–127
- aversion therapy, substance abuse treatment 170
- Bazeldon Center for Mental Health Law, concerns about mental health courts 393–394
- Beery–Buktenica Developmental Test of Visual–Motor Integration 298
- Behavior Assessment System for Children, Second Edition (BASC-II) 303
- Behavior Rating Inventory of Executive Functioning (BRIEF) 303–304
- behavioral activation, criminal behavior risk factor 128–129
- behavioral questionnaires 303–304
- benzodiazepines 326–327
- benztropine 310–311
- Big Brothers Big Sisters of America (BBBS) programs 344, 345
- biological risk factors for criminal behavior 123–127
- bipolar disorder, treatment for substance abusers 169
- Black youth *see* African-American youth
- “Boot camp” programs 376–377
- brain development, criminal behavior risk factors 123–124
- brain development in adolescents
 - and culpability 245–247
 - and the juvenile death penalty 247–249
 - influence of research findings 247–249
 - scientific findings 245–247
- bupropion 169, 170, 326 *see also* Wellbutrin
- California Verbal Learning Test–Children (CVLT-C) 300
- California Youth Authority (CYA) prisons, rates of minority youth admission 53–54
- carbamazepine 323, 324, 327
- CD *see* conduct disorder
- Central Park Jogger case (1989), false confessions 62
- child abuse, criminal behavior risk factor 132–133
- Child and Adolescent Functional Assessment Scale (CAFAS) 280
- Child and Adolescent Levels of Care Utilization Services (CALOCUS) 162–163
- Child and Adolescent Needs and Strengths–Juvenile Justice (CANS-JJ) 281
- Child Behavior Checklist (CBCL) 303
- childhood maltreatment, and compulsive behaviors 257–258
- Children’s Category Test 299
- Children’s Memory Scale (CMS) 299–300
- chlordiazepoxide 326–327
- chlorpromazine 326
- CITA (Court for the Individualized Treatment of Adolescents), mental health court model 391–394
- citalopram 325
- civil commitment, juvenile sex offenders 206
- Clinical Evaluation of Language Fundamentals–4 (CELF-4) 297
- clinical examination, differences from forensic examination 404–409
- clomipramine 325
- clonazepam 326–327
- clozapine 326
- Coalition for Juvenile Justice 55
- Cognitive Assessment System (CAS) 296, 298–299
- community-based interventions
 - 8% Early Intervention Program 378
 - advantages over residential programs 369
 - Aggression Replacement Training (ART) 373
 - “Boot camp” programs 376–377
 - co-morbid mental disorders 378
 - developmentally appropriate programs 378
 - efficacy 368–369
 - Family Functional Therapy (FFT) 374–375
 - family interventions 374–376
 - Functional Family Therapy (FFT) 347–349, 354–355
 - individual interventions 372–374
 - individualized services 378
 - information on evaluations of interventions 379
 - meta-analytic studies 369–372
 - Multidimensional Treatment Foster Care (MTFC) 349–350, 354–355, 375–376
 - Multisystemic Therapy (MST) 346–347, 354–355, 375
 - programs with minimal or negative effects 376–377
 - Project Back-on-Track 377–378
 - “Scared Straight” programs 377
 - systems approach 377–378
 - treatment programs 346–350
 - very young offenders 378
 - “Wilderness challenge” programs 376–377
 - “Wraparound” programs 378
- community influences on criminal behavior risk 134
- competence evaluation
 - choice of experts 107–109
 - court records 111
 - disclosure of data, notes, and reports 112–113
 - educational records 110–111
 - frequently requested records 110–112
 - informed consent (Waiver of Confidentiality) 112–113
 - interactions with the judge and lawyers 113–114
 - juvenile detention records 111
 - medical records 110
 - mental health treatment records 110
 - organization of the expert witness report 114–115
 - other side’s psychiatric/psychological evaluations 111–112
 - police records 111
 - referrals to experts 107–109
 - submission of the report 113–114
 - supply of records to evaluation team 109–110
- competence to stand trial
 - ability to cooperate with counsel 94–95

- ability to understand the adjudicative processes 82–84, 94
- ability to understand the nature of the charge 94
- admissibility of child’s statement 84–86
- age of the child 98
- appreciation of potential consequences of pleading 94
- bona fide doubt 90–91
- conducting a fitness evaluation 100–103
- criminal capacity 88–89
- defense lawyer’s role 95–96
- delinquency proceedings requirement 89
- developmental immaturity of the child 99–100
- due process requirement 87
- expert reports and testimony 90–92
- factors affecting 82–84
- factors that courts take into account 98–100
- history of the relevant law 80–82
- immaturity issue 82–83
- In re Gault* 80–81
- intelligence level of the child 98–99
- Jackson v. Indiana* 87
- judge’s role 97–98
- juvenile courts and due process 80–82
- legal test for competence 87–88
- McKeiver v. Pennsylvania* 81–82, 84
- mental illness or disability 99
- physical disabilities or impairments 100
- pre-trial hearing 84–86
- procedure for determination 89–93
- procedures following unfit decision 92–93
- prosecutor’s role 96–97
- psychiatric assessment 100–103
- psychological assessment 100–103
- Roper v. Simmons* 82
- ruling by the judge 92
- standards applied in juvenile courts 82–84
- standards to be applied in decision-making 93–95
- voluntariness of child’s statement 84–86
- Comprehensive Assessment of Spoken Language (CASL) 297
- Comprehensive Test of Non-verbal Intelligence (C-TONI) 296
- compulsive behaviors, and childhood maltreatment 257–258
- conduct disorder (CD)
 - adolescent-onset type 292
 - and substance abuse 151–152, 153
 - association with academic problems 291
 - childhood-onset type (life-course persistent) 292
 - influence on recidivism 292
 - neuropsychological profiles 292
 - pharmacotherapy 314–321, 324
 - relationship to ADHD 290–291
- confidentiality 402–409
 - exceptions to 409
 - forensic examination of juveniles 404–409
 - forensic psychiatry 402–404
 - parent’s right to know vs. juvenile’s right to privacy 407–408
- consent 409–413
 - and competency 411–412
 - emergency consent 413
 - informed consent definition 409–410
 - mature-minor consent 411–412
- Continuous Performance Tests (CPTs) 299
- cortisol level, criminal behavior risk factor 126
- CRAFFT screening tool 161–162
- criminal behavior
 - biological and social influences 123
 - history of inquiry into 122–123
- criminal behavior risk factors
 - academic performance 129
 - anger regulation impairment 123–124
 - autonomic nervous system 126–127
 - behavioral activation 128–129
 - biological factors 123–127
 - child abuse 132–133
 - community influences 134
 - cortisol levels 126
 - developmental risk factors 123
 - early out-of-home care 131
 - effects of exposure to multiple risks 135–136
 - emotion regulation impairment 127–128
 - environmental toxins 125
 - family violence 132–133
 - fetal exposure to drugs 125
 - gang participation 133–134
 - genetics 124–125, 126
 - heart rate marker 126–127
 - heritability of physical aggression 124–125
 - impulse control impairment 123–124
 - influences on the developing brain 123–124
 - insecure attachment in childhood 127–128
 - intelligence level 129–130
 - maladaptive parenting 129, 130–132
 - maternal smoking during pregnancy 125
 - media influences 134–135
 - neighborhood social influences 134
 - neurotransmitters and neurochemicals 125–126
 - parental disciplinary style 130
 - parental display of nurturing behavior 130–131
 - parental teaching of prosocial behavior 131
 - parenting during adolescence 131–132
 - peer relationships 133–134
 - psychological factors 127–130
 - role of monoamine oxidase A (MAOA) 126
 - serotonin levels 125–126
 - skin conductance (electrodermal response) marker 126–127
 - social cognitive functioning 130
 - social factors 130–135
 - temperament 128–129
 - testosterone levels 126
- criminal capacity, age of 88–89
- Cylert 168–169
- cypoterone acetate (CPA) 218–219
- death of adolescents, main causes 180
- death penalty for juveniles
 - 8th Amendment jurisprudence 241, 242–244

- death penalty for juveniles (cont.)
 - adolescent brain immaturity 245–247
 - “cruel and unusual punishment” determination 241, 242–245
 - evolving standards of decency 244–245, 247–249
 - history of 242–244
 - mental condition of juveniles on death row 251–252
 - scientific arguments against 247–250
 - scientific findings about the adolescent brain 245–247
 - traumatic histories of juveniles on death row 251–252
 - US Supreme Court ruling 241, 242–244
 - see also Roper v. Simmons* (2005)
- Delis–Kaplan Executive Function System (D-KEFS) 298
- depression
 - and suicide among juvenile detainees 182
 - major depressive disorder and recidivism 292
 - treatment for substance abusers 170
- Development Services Group 56
- developmental disorders and delinquency 256
- developmental risk factors
 - for criminal behavior 123
 - for substance abuse 156–159
- dextroamphetamine 328
- Diagnostic Interview Schedule for Children: Present State Voice Version (Voice DISC) 282
- Dialectical Behavior Therapy (DBT) 351–355
 - case example (Amy) 363–364
 - predictors and correlates of success 352–356
- diazepam 326–327
- Differential Ability Scale (DAS) 295
- diphenhydramine 310–311
- DISC (Diagnostic Interview Schedule for Children)
 - diagnostic tool 17–18
- discrimination, definition 48
- disparity, definition 48
- disproportionate minority confinement (DMC)
 - 48–49
 - catalog of state DMC reports 56
 - contributory factors 57
 - current state 50–55
 - discrimination (definition) 48
 - disparity (definition) 48
 - educational system factors 57
 - family factors 57
 - juvenile justice system factors 57
 - literature review 49–50
 - minority youth groups identified 49
 - national strategies to address and resolve 55–57
 - overrepresentation (definition) 48
 - overrepresentation in the juvenile justice system 51–55
 - Relative Rate Index (RRI) 56
 - research summaries 57
 - residential placement 50, 51, 52
 - socioeconomic factors 57
 - state strategies to reduce 57–58
 - website 56
- Disproportionate Representation Index (DRI) 56
- divalproex sodium 327
- diversion programs 342–344, 354–355
 - case example (Edward) 359
 - evaluation 343
 - intervention strategies and targets for change 342–343
 - predictors and correlates of success 343–344
- dopamine (D2) receptors, role in substance abuse 155–156
- double jeopardy risk in the criminal justice system 61
- Drug Abuse Resistance Education (DARE) program 149
- drug courts 394–398
- Drug Usage Screening Inventory (DUSI) 162
- drug withdrawal 258–259
- drugs
 - effects of fetal exposure 125, 171–172, 257
 - Juvenile Alcohol and Marijuana Diversion Program 398
 - juvenile drug courts 394–398
- DSM approach to psychopharmacology
 - evaluation 312
- dyslexia
 - confusion with ADHD/ADD 157
 - substance abuse risk factor 157
- early intervention programs 342–345, 354–355
 - diversion programs 342–344, 354–355
 - mentoring programs 344–345, 354–355
 - substance abuse prevention 149–150
- education
 - benefits of completing high school or GED 236
 - difficulty of provision in juvenile facilities 235–236
 - effective services for juvenile detainees 237–239
 - effects of incarceration 232–234
 - learning difficulties among juvenile offenders 232–234
 - provision for juvenile detainees 234–236
 - rights of juvenile detainees 234–235
 - transition back into the community 236, 238
 - see also schools*
- educational consultants *see* expert referrals
- effective treatment strategies
 - clinical supervision 356–357
 - collaboration with stakeholders 357
 - key elements 356–358
 - policy recommendations and future direction 358
 - qualities of effective providers 356
 - training and protocol adherence 356
- effexor 169
- emotion regulation impairment, criminal behavior risk factor 127–128
- emotional abuse, and suicide among juvenile detainees 185–186
- empirically supported treatment 340
 - characteristics 340

- community-based treatment programs 346–350
- early intervention programs 342–345, 354–355
- framework for evaluation of programs 341
- policy recommendations and future direction 358
- promising transition programs 350–355
- risk factor identification 341
- Enmund v. Florida* (1982) 243
- environmental toxins, criminal behavior risk factors 125
- epilepsy 256
- eszopiclone 327
- ethical issues
 - competency and consent 411–412
 - confidentiality 402–409
 - confidentiality in forensic examination of juveniles 404–409
 - confidentiality in forensic psychiatry 402–404
 - consent 409–413
 - emergency consent 413
 - exceptions to confidentiality 409
 - informed consent definition 409–410
 - mature-minor consent 411–412
 - parent’s right to know vs. juvenile’s right to privacy 407–408
 - restraints and seclusions 417–420
 - right to refuse treatment 415–417
 - right to treatment 413–415
- evidence-based interventions, need for 340
- executive functioning
 - deficits associated with delinquency 288–289
 - tests of 298–299
- expert referrals
 - choice of experts 107–109
 - competence evaluation 107–109
 - court records 111
 - disclosure of data, notes, and reports 112–113
 - educational records 110–111
 - expert witness report 114–115
 - informed consent (Waiver of Confidentiality) 112–113
 - interactions with the judge and lawyers 113–114
 - juvenile detention records 111
 - medical records 110
 - mental health treatment records 110
 - other side’s psychiatric/psychological evaluations 111–112
 - police records 111
 - records required 110–112
 - submission of the report 113–114
 - supply of records to evaluation team 109–110
 - see also* forensic examination; post-adjudicatory evaluation
- expert witnesses
 - organization of report 114–115
 - preparation to testify 115
- extra-pyramidal side effects of medication 310–311, 326
- false confessions
 - Central Park Jogger case (1989) 62
- effects of police interrogation technique 66–72
- vulnerability of juveniles 62–63, 67–70
- vulnerability of the mentally ill or impaired 62–63, 67, 70–72
- Family Functional Therapy (FFT) 374–375
 - see also* Functional Family Therapy
- Family Integrated Therapy (FIT) 350–351, 354–355
 - case example (Julio) 362–363
 - predictors and correlates of success 351
- family interventions 374–376
- family therapy, substance abuse treatment 165
- family violence, criminal behavior risk factor 132–133
- fetal alcohol effects 171–172
- fetal alcohol syndrome 171–172
- fetal exposure to alcohol 257
- fetal exposure to drugs, criminal behavior risk factor 125
- fetal exposure to illicit drugs 257
- fluoxetine 170, 325
- fluphenazine 326
- fluvoxamine 325
- forensic examination
 - differences from clinical examination 404–409
 - of court-involved juveniles 404–409
 - see also* expert referrals; post-adjudicatory evaluation
- Functional Family Therapy (FFT) 165, 347–349, 354–355
 - case example (Terrance) 361–362
 - evaluation 348–349
 - intervention strategies and targets for change 348
 - predictors and correlates of success 349
 - see also* Family Functional Therapy
- Furman v. Georgia* (1972) 242
- Gallegos v. Colorado* (1962) 85–86, 103
- gang participation, criminal behavior risk factor 133–134
- general intelligence tests 293–296
- genetic disorders and delinquency 256–257
- genetic risk factors
 - for criminal behavior 124–125, 126
 - for substance abuse 154–156
- Global Appraisal of Individual Needs-Quick (GAIN-Q) 283–284
- Global Appraisal of Individual Needs-Short Screener (GAIN-SS) 278–279
- guanfacine 168–169
- Gun Free Schools Act (1994) 230–231
- Haley v. Ohio* (1948) 85–86, 103
- haloperidol 310–311, 326
- Haywood Burns Institute 57
- head trauma and delinquency 256
- heart rate, marker for criminal behavior risk 126–127
- Hispanic/Latino youth
 - data collection initiative 56
 - disproportionate minority confinement 49–50
 - lack of separate data 51–52, 53
 - lack of separate data on DMC 54–55

Hispanic/Latino youth (cont.)
 proportion of juvenile population 51–52
 residential placement rates 50, 51, 52
 suicidal behavior in confinement 186
 see also minority youth
HIV infection 258–259
HIV testing 262
human papilloma virus vaccination 263
hypnotics, second generation 327

ICD-10 approach to psychopharmacology
 evaluation 312
IDEA (Individuals with Disabilities Education Act, 1975) 234–235
illicit drug use 258–259
impulse control impairment, criminal behavior risk factor 123–124
In re Gault 80–81
individual interventions 372–374
injection drug use, and childhood maltreatment 257–258
insecure attachment in childhood, criminal behavior risk factor 127–128
intelligence level, and criminal behavior risk 129–130
intervention programs, questions of efficacy 368–369
IQ tests 293–296

Jackson v. Indiana (1972) 87
Jacob Wetterling Act (1994) 205
jail, definition 180–181
jails
 causes of death 181–182
 suicide rates 181–182
JUMP initiative 344–345
Jump Start program 150
justice-involved youth
 increasing harshness of treatment 62
 mental health problems 62
 number of juvenile interactions with police 61–62
 police interrogation technique 62–63, 67–70
 substance use problems 62
 vulnerability to false confessions 62, 67–70
 vulnerability under police interrogation 61, 62
 see also juvenile offenders
Juvenile Alcohol and Marijuana Diversion Program 398
juvenile detainees, constitutional right to mental health services 7
Juvenile Justice and Delinquency Prevention Act (1974) 55
Juvenile Justice Delinquency and Prevention Act (2002) 48–49
Juvenile Justice Evaluation Center 56
juvenile justice system
 alternatives to traditional adjudication 385
 goal of rehabilitation 385
 implications of psychiatric disorder studies 39–40
 inconsistent assessment of juveniles 423–424
Juvenile Alcohol and Marijuana Diversion Program 398
juvenile drug courts 394–398
juvenile mental health courts 390–394
parens patriae and police power 423
post-adjudicatory evaluation 424–425
restorative justice conferences 389–390
restorative justice model 385
right to treatment 413–415
therapeutic jurisprudence model 390–394
trend towards punishment 385
youth courts 386–389
juvenile mental health courts 390–394
juvenile offenders
 benefits of completing high school or GED 236
 common characteristics 232–234
 demographic data 230
 dropout rate after release 236
 dropout rate from school 231–232
 educational challenges 232–234
 educational challenges for juvenile facilities 235–236
 educational rights while incarcerated 234–235
 educational services while incarcerated 234–236
 effective educational services 237–239
 effects of incarceration on education 232–234
 history of severe academic difficulties 232–234
 impact of suspension or expulsion from school 231–232
 impact of zero-tolerance policies in schools 230–232
 pattern of school dropout 232–234
 prevalence of learning disabilities 232–234
 proportion of females 230
 proportion of juvenile population 229–230
 transition back into the community 236, 238
 vulnerability under police interrogation 61, 62
 see also justice-involved youth; very young offenders
juvenile population
 arrest rate 229–230
 projected increase in 229
 proportion of offenders 229–230
 size of (US) 229

Kansas v. Hendricks 206
Kaufman Assessment Battery for Children-Second Edition (KABC-II) 296
Klinefelter's syndrome 256–257

language function tests 297–298
language processing problems, substance abuse risk factors 157
Latino youth *see* Hispanic/Latino youth
lead exposure from retained bullets 257, 258
learning and memory tests 299–300
learning disability testing 300–301
learning disorder, substance abuse risk factor 154, 157
Leiter International Performance Scale-Revised (Leiter-R) 296

443 Index

- leuprolide 218–219
- life skills training 149
- lithium 169, 320–321, 323, 324, 327
- lorazepam 310–311, 326–327
- low self-esteem, substance abuse risk factor 158
- loxapin 326
- luteinizing hormone-releasing hormone (LHRH) 218–219
- major depressive disorder, influence on recidivism 292
- malingering 262–263
- marijuana use, and schizophrenia 153
- Massachusetts Youth Screening Instrument-Version 2 (MAYSI-2) 162, 277–278, 314
- maternal smoking during pregnancy, criminal behavior risk factor 125
- McKeiver v. Pennsylvania* 81–82, 84
- media influences
 - and substance abuse 150
 - criminal behavior risk factors 134–135
- medical care, needs of incarcerated youth 255
- medical problems resulting from delinquency 257–259
 - drug withdrawal 258–259
 - HIV infection 258–259
 - illicit drug use 258–259
 - lead from retained bullets 258
 - orthopedic injuries 258
 - post-traumatic injuries 258
 - pregnancy 258–259
 - serious long-term problems 258
 - sexually transmitted infections 258–259
- medical problems which may cause delinquency 255–257
 - developmental disorders 256
 - epilepsy 256
 - fetal exposure to alcohol 257
 - fetal exposure to illicit drugs 257
 - genetic disorders 256–257
 - head trauma 256
 - history of physical child abuse 256
 - Klinefelter’s syndrome 256–257
 - lead exposure 257
 - temporal lobe epilepsy 256
- medical research, studies involving prisoners 263–264
- medical screening on arrival in detention 259–263
 - abdominal pain 260
 - appendicitis 261
 - asthma 260
 - cardiac disease 260
 - chest pain 260
 - chlamydia 259–260
 - chronic medical problems 263
 - constipation 261
 - deafness 262
 - dental care needs 262
 - dermatologic problems 261–262
 - dysmenorrhea 261
 - endometriosis 261
 - gonorrhea 259–260
 - headaches 260
 - health maintenance procedures 263
 - hepatitis 261
 - human papilloma virus vaccination 263
 - hypertension 262
 - hyperthyroidism 260
 - immunizations 263
 - leukemia 262
 - lower quadrant pain in females 261
 - medication toxicity 261
 - meningococcal immunization 263
 - MRSA skin infections 261–262
 - obesity in adolescents 262
 - offer of HIV testing 262
 - organ disease 262
 - painful urination in boys 261
 - pelvic inflammatory disease 259–260, 261
 - pelvic pain in females 261
 - peptic ulcers 260
 - pertussis vaccination 263
 - pneumothorax 260
 - pregnancy 260
 - reasons for malingering 262–263
 - renal failure 262
 - rheumatic problems 262
 - sexually transmitted infections 261
 - skin conditions 261–262
 - testicular pain 261
 - torsion of the testis 261
 - tuberculosis 259
 - tumors 262
 - visual problems 262
 - vomiting 261
- medroxyprogesterone acetate (MPA) 218–219
- Megan’s Law (1996) 205
- memory and learning tests 299–300
- meningococcal immunization 263
- mental disability
 - and culpability 243–244
 - and death penalty 243–244
 - and police interrogation technique 62–63, 67, 70–72
 - vulnerability under police interrogation 61
 - vulnerability to false confessions 62–63, 67, 70–72
- mental health assessment in juvenile justice
 - distinguishing from screening 272–273, 275
 - further detailed information 271
 - process 275
 - purpose 275
- mental health courts for juveniles 390–394
- mental health problems among justice-involved youth 62
- mental health screening in juvenile justice
 - delinquency prevention and rehabilitation 271
 - difficulty of disorder identification in juveniles 272
 - distinguishing from assessment 272–273
 - further detailed information 271
 - health and welfare benefits 271

- mental health screening in juvenile justice (cont.)
 - indication of need for mental health services 271–272
 - numbers of youth in custody 270
 - prevalence of mental disorders 270
 - process 274
 - purposes 273–274
 - reasons for identifying mental health problems 270, 271–272
 - results and responses 274
 - safety benefits 271
 - what it does not do 274
- mental health screening tools
 - Child and Adolescent Functional Assessment Scale (CAFAS) 280
 - Child and Adolescent Needs and Strengths – Juvenile Justice (CANS-JJ) 281
 - Diagnostic Interview Schedule for Children: Present State Voice Version (Voice DISC) 282
 - Global Appraisal of Individual Needs-Quick (GAIN-Q) 283–284
 - Global Appraisal of Individual Needs-Short Screener (GAIN-SS) 278–279
 - instruments available 276–284
 - Massachusetts Youth Screening Instrument-Version 2 (MAYSI-2) 277–278
 - multidimensional brief screening tools 277–279
 - multidimensional scales identifying clinical disorder 281–284
 - Practical Adolescent Dual Diagnosis Interview (PADDI) 282–283
 - problem- or needs-oriented schedules 279–281
 - Problem-Oriented Screening Instrument for Teenagers (POSIT) 279–280
 - selection criteria 275–276
 - unidimensional (single-focused) tools 277
- mental health services, availability in juvenile facilities 188–189
- mentoring programs 344–345, 354–355
 - case example (Tina) 359–360
 - evaluation 345
 - intervention strategies and targets for change 344–345
 - predictors and correlates of success 345
- methylphenidate 168–169, 328
- Millon Adolescent Clinical Inventory (MACI) 302–303
- Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-A) 302
- minority youth
 - overrepresentation in the juvenile justice system 51–55
 - rates of admission to state prison 54
 - rates of arrest 52, 53
 - rates of offending and arrest 54
 - rates of sentencing to CYA prisons 53–54
 - rates of transfer to adult court 53–54
 - see also* African-American youth; American-Indian youth; Asian-American youth; disproportionate minority confinement; Hispanic/Latino youth; Pacific Islander youth
- Miranda rights
 - child's competence to waive rights 86
 - frequency of waiver among children 105–106
 - issuance of Miranda warning 63, 64–66
 - knowing, voluntary and intelligent waiver 106–109
 - protocol for a competence examination 106–109
 - research on children's competence to waive rights 105–106
 - research on children's understanding 105–106
 - voluntariness of child's statement 84–86
 - waiver by children under police interrogation 63, 65–66, 103–105
- Miranda v. Arizona* (1966) 86, 103–105
- Miranda warning comprehension
 - case example (Adam, age 16) 116–117
 - case example (Jennifer, age 14) 117–119
 - case example (John, age 12) 115–116
- modafinil 169
- molindone 326
- monoamine oxidase A (MAOA), role in criminal behavior risk 126
- mood disorders, and substance abuse 151–152
- mood stabilizers 320–321, 327
- motivational enhancement therapy (MET) 161, 164
- multidimensional family therapy 165
- Multidimensional Treatment Foster Care (MTFC)
 - 349–350, 354–355, 375–376
 - evaluation 350
 - intervention strategies and targets for change 349–350
- multiple systems therapy 165
- Multisystemic Therapy (MST) 165, 346–347, 354–355, 375
 - case example (Tiffany) 360–361
 - evaluation 347
 - intervention strategies and targets for change 346–347
 - predictors and correlates of success 347
- naltrexone 170
- National Crime Victimization Survey, minority youth offending and arrest rates 54
- National Incident-Based Reporting System, minority youth arrest rate 54
- Native American youth, suicidal behavior in confinement 186 *see also* American-Indian youth; minority youth
- neighborhood influences on criminal behavior risk 134
- neurobiology of addiction 154–156
- neuropsychological deficits
 - association with delinquency 288–290
 - association with recidivism 292
 - in co-morbid ADHD and delinquency 290–291
- neurotransmitters and neurochemicals, criminal behavior risk factors 125–126
- non-verbal intelligence tests 296
- Northwestern Juvenile Project (prevalence of psychiatric disorders) 1, 7, 16–25, 26–27, 30, 32–33

- ADHD diagnoses 17–18
- age differences in SUDs (substance use disorders)
 - with major mental disorders 35
- co-morbidity of SUDs 37
- co-morbidity of SUDs and major mental disorders 34, 37
- comparisons with the general population 36–37
- DISC diagnostic tool 17–18
- discussion 36–37
- future research 38–39
- limitations to the study 37–38
- mean age of subjects 16–17
- methods 16–17
- potential underestimation of prevalences 36
- prevalence rates by age 23–33, 37
- prevalence rates by race/ethnicity 21–23, 24–25, 26–27, 37
- prevalence rates by sex 18, 18–21, 22, 23, 37
- prevalence rates of depressive disorders 37
- prevalence rates of PTSD 34, 36–37
- prevalence rates of trauma 34, 36–37
- psychiatric diagnoses 17–18
- psychosis diagnoses 17
- PTSD diagnoses 18
- race/ethnic composition of sample 16–17
- racial/ethnicity differences in SUDs with major mental disorders 35
- rates of major mental disorders among youth with SUDs 35
- rates of SUDs with major mental disorders 34–35, 37
- relative onset of major mental disorders and SUDs 35–36
- results 18, 18–25, 26–27, 30, 32–33
- sample of subjects 16–17
- sex composition of sample 16–17
- sex differences in SUDs with major mental disorders 35
- statistical analysis 18
- nortriptyline 168–169
- obesity among adolescents 262
- odansetron 170
- Office of Juvenile Justice and Delinquency Prevention, DMC initiatives 55–57
- olanzapine 310–311, 323, 326
- out-of-home care, and criminal behavior risk 131
- overrepresentation, definition 48
- Pacific Islander youth, proportion of juvenile population 51–52 *see also* Asian-American youth; minority youth
- Pam Lynchner Sexual Offender Tracking and Identification Act (1996) 205
- parens patriae doctrine 411
 - and police power 423
- parental disciplinary style, criminal behavior risk factors 130
- parental display of nurturing behavior, criminal behavior risk factors 130–131
- parental teaching of prosocial behavior 131
- parenting during adolescence, and criminal behavior risk 131–132
- parenting methods, criminal behavior risk factors 129, 130–132
- paroxetine 325
- Patient's Bill of Rights* 413–414
- peer courts *see* youth courts
- peer jury *see* youth courts
- peer relationships, criminal behavior risk factors 133–134
- Penry v. Lynaugh* (1989) 244
- personality questionnaires 301–303
- pertussis vaccination 263
- pharmaceutical treatments for juvenile sex offenders 218–219 *see also* psychopharmacology
- pharmacotherapy, for conduct disorder 314–321, 324 *see also* psychopharmacology
- physical abuse, and suicide among juvenile detainees 185–186
- physical aggression, heritability of 124–125
- physical child abuse, and delinquency 256
- pimozide 326
- PIP (positive, instrumental, or planned) aggression 311–312
- police, number of juvenile interactions with 61–62
- police interrogation
 - admissibility of child statements 103–105
 - court concerns about child confessions 103–105
 - means to protect children's rights 103–105
 - vulnerability of mentally ill people 61
 - vulnerability of young people 61, 62
 - waiver of Miranda rights by children 103–105
- police interrogation process
 - child's ability to understand 84–86
 - Gallegos v. Colorado* (1962) 85–86
 - Haley v. Ohio* (1948) 85–86
 - Miranda v. Arizona* (1966) 86
 - Powell v. Alabama* (1932) 85
 - voluntariness of child's statement 84–86
- police interrogation technique 62–67
 - case example (Adam, age 16) 116–117
 - case example (Jennifer, age 14) 117–119
 - case example (John, age 12) 115–116
 - double jeopardy in the interrogation room 61, 72–74
 - false confessions 62
 - formal interrogation process 64, 66–67
 - gaining of Miranda rights waiver 63, 65–66
 - generation of false confessions 66–72
 - issuance of Miranda warning 63, 64–66
 - pre-interrogation interview 63–65
 - psychological tactics 66–67
 - recommendations to protect the vulnerable 72–74
 - Reid technique 63
 - stages 63
 - treatment of juveniles 62–63, 67–70
 - treatment of the mentally ill or impaired 62–63, 67, 70–72
- post-adjudicatory evaluation
 - assessment instruments 432–433

- post-adjudicatory evaluation (cont.)
 - court referral and structure of evaluation 425–426
 - evaluation process 431–434
 - factors affecting recidivism 427–431
 - factors that affect disposition 426–427
 - function 424–425
 - residential and community facilities 427–431
- Powell v. Alabama* (1932) 85
- Practical Adolescent Dual Diagnosis Interview (PADDI) 282–283
- pregnancy 258–259
- premoline 328
- prenatal exposure to alcohol 171–172
- prison, definition 180–181
- prisons
 - causes of death 181–182
 - suicide rates 181–182
- Problem-Oriented Screening Instrument for Teenagers (POSIT) 162, 279–280
- Project Back-on-Track 377–378
- Project SMART 149
- Project STAR 149
- psychiatric co-morbidity, juvenile sex offenders 204
- psychiatric disorder studies
 - implications for the juvenile justice system 39–40
 - Northwestern Juvenile Project 16, 16–25, 26–27, 30, 32–33
 - prevalence studies since 1990 7–15
- psychiatric disorders
 - and suicide among juvenile detainees 182, 184–185
 - co-occurring substance abuse disorders 146–147
 - diagnoses in delinquent youth 17–18
 - lack of resources for treatment 146
 - prevalence among juvenile offenders 146–147
- psychiatric evaluation *see* expert referrals
- psychological assessment tools 293–304
 - academic achievement tests 300–301
 - adaptive functioning tests 301
 - Adolescent Psychopathology Scale (APS) 302, 303
 - Adolescent Test of Problem-Solving (TOPS-A) 297–298
 - Beery–Buktenica Developmental Test of Visual-Motor Integration 298
 - Behavior Assessment System for Children, Second Edition (BASC-II) 303
 - Behavior Rating Inventory of Executive Functioning (BRIEF) 303–304
 - behavioral questionnaires 303–304
 - California Verbal Learning Test-Children (CVLT-C) 300
 - Child Behavior Checklist (CBCL) 303
 - Children’s Category Test 299
 - Children’s Memory Scale (CMS) 299–300
 - Clinical Evaluation of Language Fundamentals-4 (CELF-4) 297
 - Cognitive Assessment System (CAS) 296, 298–299
 - Comprehensive Assessment of Spoken Language (CASL) 297
 - Comprehensive Test of Nonverbal Intelligence (C-TONI) 296
 - Continuous Performance Tests (CPTs) 299
 - Delis–Kaplan Executive Function System (D-KEFS) 298
 - Differential Ability Scale (DAS) 295
 - executive functioning tests 298–299
 - general intelligence tests 293–296
 - IQ tests 293–296
 - Kaufman Assessment Battery for Children-Second Edition (KABC-II) 296
 - language function tests 297–298
 - learning and memory tests 299–300
 - learning disability testing 300–301
 - Leiter International Performance Scale-Revised (Leiter-R) 296
 - memory and learning tests 299–300
 - Millon Adolescent Clinical Inventory (MACI) 302–303
 - Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-A) 302
 - non-verbal intelligence tests 296
 - personality questionnaires 301–303
 - Stanford-Binet, Fifth Edition (SB5) 295
 - Stroop test 299
 - Test of Non-verbal Intelligence-3 (TONI-3) 296
 - Tower of Hanoi 299
 - Tower of London 299
 - Trails B 299
 - Universal Non-verbal Intelligence Test (UNIT) 296
 - Vineland-II Adaptive Behavior Scales 301
 - visual-motor tests 298
 - visual-spatial tests 298
 - Wechsler Individual Achievement Test-II 300
 - Wechsler Intelligence Scales 294, 295, 298–299, 300
 - Wechsler Memory Scale-III (WMS-III) 299–300
 - Wide Range Achievement Test-Third Edition 300–301
 - Wide Range Assessment of Memory and Learning (WRAML) 300
 - Wisconsin Card Sorting Test 299
 - Woodcock-Johnson-III, Tests of Achievement 300
 - Woodcock-Johnson-III, Tests of Cognitive Ability (WJ-III) 294–295, 298–299, 300
- psychological distress, and suicide among juvenile detainees 184
- psychological evaluation *see* expert referrals
- psychological risk factors for criminal behavior 127–130
- psychopathology
 - potential benefits from psychopharmacology 309–310
 - rates among juvenile offenders 308
 - treatment approaches for juvenile offenders 308–309
 - treatment of acute aggression 309, 310–311
- psychopharmacology
 - antidepressants 325

Cambridge University Press

978-0-521-61290-6 - The Mental Health Needs of Young Offenders: Forgoing Paths toward Reintegration and Rehabilitation

Edited by Carol L. Kessler and Louis J. Kraus

Index

[More information](#)

447

Index

- antipsychotics 326
- atomoxetine 328
- atypical antipsychotics 326
- benzodiazepines 326–327
- classes of medication 320–321, 325–328
- DSM approach to evaluation 312
- evaluation and assessment for 312–314
- extra-pyramidal side effects 310–311, 326
- for aggression in juvenile delinquents 310–311
- ICD-10 approach to evaluation 312
- in integrated service provision 309–310
- integrated treatment planning 329–330, 331
- interventions for juvenile offenders 309–310
- interventions for suicidal behavior 328–329
- intramuscular (IM) formulations 310–311
- mood stabilizers 320–321, 327
- oral medications 310
- PIP aggression 311–312
- RADI aggression 311–312
- second generation hypnotics 327
- side effects 310–311
- SSRIs 325
- stimulants 328
- substance abuse treatment 168–170
- typical antipsychotics 326
- psychosis diagnosis in delinquent youth 17
- PTSD (posttraumatic stress disorder) diagnosis in delinquent youth 18
- quetiapine 323, 326
- racial composition of US juvenile population 51–52
- racial differences, suicidal behavior among juvenile detainees 186
- RADI (reactive, affective, defensive, or impulsive) aggression 311–312
- recidivism
 - among sex offenders 221–222
 - association with neuropsychological deficits 292
 - in early- and late-onset conduct disorder 292
 - influence of major depressive disorder 292
- referrals to experts *see* competence evaluation
- rehabilitation goal of the juvenile justice system 385
- Research and Evaluation Associates 55–56
- residential placement, disproportionate minority confinement 50, 51, 52
- restorative justice conferences 389–390
- restraints (physical and chemical) and seclusions 417–420
 - contraindications 418–419
 - definition 417
 - guidelines and policies 417–418
 - implications for youths with history of abuse/trauma 419
 - indications 418–419
- risperidone 310, 315–323, 326
- Roper v. Simmons* (2005) 82, 241, 244, 245
 - amicus briefs on juveniles and the death penalty 249–250
 - US Supreme Court opinion 250–251
- “Scared Straight” programs 377
- schizophrenia, and substance abuse 153
- schools
 - dropout patterns 232–234
 - dropout rates after suspension 231–232
 - effects of incarceration on education 232–234
 - Gun Free Schools Act (1994) 230–231
 - impact of suspensions and expulsions on students 231–232
 - impact of zero-tolerance policies 230–232
 - see also* education
- science
 - findings about the adolescent brain 245–247
 - informing policy and legislative decisions 247–250
 - research on juveniles on death row 251–252
 - role in evolving standards of decency 247–249
- screening tools, substance abuse assessment 161–162 *see also* mental health screening tools; psychological assessment tools
- seclusions *see* restraints (physical and chemical) and seclusions
- selective serotonin reuptake inhibitors *see* SSRIs
- self-esteem level, substance abuse risk factor 158
- serotonin level, criminal behavior risk factor 125–126
- sertraline 325
- sex offender evaluation 215–218
 - assessment instruments 216–217
 - interview and collateral information 215–216
 - phallometric assessment 217–218
 - physiological assessment 217–218
 - polygraphy 218
 - psychological and actuarial testing 216–217
- sex offender treatments 218–222
 - anti-hormone therapies 218–219
 - biological 218–219
 - chemical castration 218–219
 - cyproterone acetate (CPA) 218–219
 - example program from Colorado 221
 - leuprolide 218–219
 - luteinizing hormone-releasing hormone (LHRH) 218–219
 - major intervention techniques 220–221
 - medroxyprogesterone acetate (MPA) 218–219
 - pharmaceutical 218–219
 - psychoeducational/therapeutic modalities 220–221
 - psychosocial therapies 219–220
 - recidivism issues 221–222
 - selective serotonin reuptake inhibitors (SSRIs) 218–219
- sexual abuse, and suicide among juvenile detainees 185–186
- sexual offending by juveniles
 - categorization of sex offenders 200–201
 - civil commitment 206
 - definition 198
 - demographic data 198–199
 - developmental influences 202–204
 - etiology 199–200

sexual offending by juveniles (cont.)
female offenders 201
historical attitudes 198
history of victimization 202–203
Kansas v. Hendricks 206
legal issues 204–205
literary example (*Sanctuary* by William Faulkner) 203–204
psychiatric co-morbidity 204
rates of offending 199
registration of juvenile offenders 205–206
risk factors for 202–203
sexually violent predator laws 205, 206
theories on causes 199–200
treatment in the adult system 204–205
treatment in the juvenile justice system 204–205
very young offenders 201–202

sexual offense types and case examples 206–215
coprophilia (feces) 212
exhibitionism 211
fetishism 211–212
klismaphilia (enemas) 212
necrophilia 212, 214–215
necrophilia (case example) 215
paraphilias 209–212
paraphilias not otherwise specified 212–215
partialism (focus on a part of the body) 212
pedophilia 209–210
rape 207–208
rape (case example) 208
sadism 211
sexual homicide 208–209
sibling incest 207
telephone scatologia (obscene phone calls) 212
transvestic fetishism 212
urophilia (urine) 212
voyeurism 210
zoophilia (animals) 212–213
zoophilia (case example one) 213–214
zoophilia (case example two) 214
zoophilia juvenile death penalty case (1642) 213

sexually transmitted infections 258–260, 261
sexually violent predator laws 205, 206
Simmons see *Roper v. Simmons* (2005)
skin conductance (electrodermal response), marker for criminal behavior risk 126–127
smoking, and history of childhood maltreatment 257–258
social cognitive functioning, and criminal behavior risk 130
social risk factors for criminal behavior 130–135
social skills impairment, substance abuse risk factors 158
social workers see expert referrals
SSRIs (selective serotonin reuptake inhibitors) 218–219, 325
and suicide risk 325, 329
Stanford-Binet, Fifth Edition (SB5) 295
Stanford v. Kentucky (1989) 242–243, 244–245
stimulants 328
Stroop test 299

substance abuse
among justice-involved youth 62
and ADHD 151, 153, 156–157
and anxiety disorders 151, 152–153
and conduct disorders 151–152, 153
and learning disorders 154
and mood disorders 151–152
and poor academic achievement 154
and schizophrenia 153
co-morbid psychiatric disorders 146–147, 151
media influences 150
rates among juvenile offenders 146–147
relation to onset of co-morbid disorders 151
suicide risk 153–154, 184–185

substance abuse assessment
Adolescent Drinking Inventory (ADI) 161–162
Child and Adolescent Levels of Care Utilization Services (CALOCUS) 162–163
CRAFT screening tool 161–162
Drug Usage Screening Inventory (DUSI) 162
fetal alcohol effects 171–172
fetal alcohol syndrome 171–172
interventions for different stages 161
level of care recommendation 162–163
Massachusetts Youth Screening Instrument-Second Version (MAYSI-2) 162
motivation for treatment 161
Problem Oriented Screening Instrument for Teenagers (POSIT) 162
readiness to change 161
screening tools 161–162
stage of use 159–161
Teen Addiction Severity Index 162

substance abuse prevention
data-driven programs 149–150
Drug Abuse Resistance Education (DARE) program 149
early intervention programs 149–150
institution-driven programs 149
interventions for co-morbid disorders 151
Jump Start program 150
Life Skills Training 149
missed opportunities in the education system 154
Project SMART 149
Project STAR 149
protective factors 148–149
risk factors 147–149
study of juvenile offenders 150
theory-driven programs 149

substance abuse risk factors
academic failure 158
adolescent neurobiological changes 158–159
age of exposure to substances of abuse 156–157
age of intervention for learning disorder 157
biogenetic factors 148
cultural/societal 147
developmental factors 156–159
dyslexia 157
genetic factors 154–156

- interpersonal factors 147–148
- language processing problems 157
- neurobiology of addiction 154–156
- poor social skills and self-esteem 158
- psychobehavioral antecedents and lifetime consequences 148
- psychobehavioral factors 148
- role of dopamine (D2) receptors 155–156
- temperament/personality traits 158
- substance abuse treatment 163–170
 - 12 step programs 167–168
 - alcoholism treatment 170
 - and ADHD treatments 168–169
 - and bipolar disorder treatments 169
 - and treatments for co-morbidities 168–170
 - atomoxetine 168–169
 - aversion therapy 170
 - behavioral therapy 165
 - bupropion 169, 170 *see also* Wellbutrin
 - cognitive behavioral therapy 166
 - Cylert 168–169
 - depression treatment 170
 - effexor 169
 - family systems therapy 165
 - family therapy 165
 - fluoxetine 170
 - functional family therapy 165
 - guanfacine 168–169
 - individual behavior therapy 167
 - lithium 169
 - methylphenidate 168–169
 - modafinil 169
 - motivational enhancement therapy (MET) 164
 - multidimensional family therapy 165
 - multiple systems therapy 165
 - multisystemic therapy 165
 - naltrexone 170
 - nortriptyline 168–169
 - odansetron 170
 - psychoeducational treatment 166
 - psychopharmacology 168–170
 - structural-strategic therapy 165
 - tenex 169
 - Treatment Accountability and Safer Communities Program 168
 - valproate 169
 - venlafaxine 168–169
 - Wellbutrin 168–169 *see also* bupropion
 - withdrawal effects 170
- suicidal behavior
 - non-fatal attempts 186–187
 - pharmacological interventions 328–329
 - racial differences 186
 - self-harm behavior 186–187
 - suicidal ideation 186–187
- suicide among juvenile detainees
 - availability of mental health services 188–189
 - depression risk factor 182
 - factors associated with suicidal behavior 184
 - future directions for research 190–191
 - Hayes' survey for OJJDP 183–184
 - history of emotional abuse 185–186
 - history of physical abuse 185–186
 - history of sexual abuse 185–186
 - levels of psychological distress 184
 - mental health assessment procedures 188–189
 - potential preventative interventions 190–191
 - prevention programs 191–193
 - psychiatric risk factors 182
 - rates of psychiatric disorders 184–185
 - risk factors 182
 - substance abuse 184–185
 - typical circumstances 182
- suicide prevention programs, effectiveness 191–193
- suicide rates
 - among adolescents (US) 180
 - among juvenile detainees 181–182
 - by type of institution 189–190
 - in US jails and prisons 181–182
- suicide risk, and SSRIs 325, 329
- Teen Addiction Severity Index 162
- teen courts *see* youth courts
- temperament/personality
 - criminal behavior risk factors 128–129
 - substance abuse risk factors 158
- temporal lobe epilepsy 256
- tenex 169
- Test of Non-verbal Intelligence-3 (TONI-3) 296
- testosterone level, criminal behavior risk factor 126
- tests *see* psychological assessment tools
- therapeutic jurisprudence model 390–394
- thioridazine 326
- thiothixene 326
- Thomson v. Oklahoma* (1988) 242–243
- thorazine 310–311
- Tower of Hanoi 299
- Tower of London 299
- Trails B 299
- treatment
 - right to 413–415
 - right to refuse 415–417
- Treatment Accountability and Safer Communities Program 168
- trifluoperazine 326
- Trop v. Dulles* (1958) 244
- typical antipsychotics 326
- US Supreme Court
 - evolving standards of decency 244–245, 247–249
 - influence of research into brain development 247–251
 - ruling on juvenile death penalty 241, 242–244
- Universal Non-verbal Intelligence Test (UNIT) 296
- valproate 169, 323, 324
- venlafaxine 168–169
- verbal skills deficits
 - association with delinquency 289–290
 - association with underachievement 290–291
- very young offenders
 - community-based interventions 378

450 Index

- very young offenders (cont.)
 - restorative justice conferences 389–390
 - vulnerability under police interrogation 61, 62
- Vineland-II Adaptive Behavior Scales 301
- Violent Crime Index, minority youth arrest rate 53
- visual-motor tests 298
- visual-spatial tests 298
- Vocational Rehabilitation Act (1973)
 - (Section 504) 234
- Wechsler Individual Achievement Test-II 300
- Wechsler Intelligence Scales 294, 295, 298–299, 300
- Wechsler Memory Scale-III (WMS-III) 299–300
- Wellbutrin 168–169 *see also* bupropion
- White youth
 - proportion of juvenile population 51–52
 - rates of admission to state prisons 54
 - rates of arrest 52, 53
 - rates of detention 53
 - rates of petitioning 53
 - rates of residential placement 50, 51, 52
 - rates of sentencing to CYA prisons 53–54
 - rates of transfer to adult court 53–54
 - suicidal behavior in confinement 186
- Violent Crime Index arrest rate 53
- Wide Range Achievement Test-Third Edition 300–301
- Wide Range Assessment of Memory and Learning (WRAML) 300
- “Wilderness challenge” programs 376–377
- Wisconsin Card Sorting Test 299
- withdrawal effects, substance abuse treatment 170
- Woodcock-Johnson-III, Tests of Achievement 300
- Woodcock-Johnson-III, Tests of Cognitive Ability (WJ-III) 294–295, 298–299, 300
- “Wraparound” programs 378
- youth courts 386–389
- Youth Law Center 56
- zaleplon 327
- ziprasidone 310–311, 326
- zolpidem 327